FLORHAM PARK, N.J., Oct. 10, 2017 -- Hisamitsu America, a division of Hisamitsu Pharmaceutical Co., Inc., and the manufacturers of the popular, unscented Salonpas® Lidocaine 4% Pain Relieving Patch, the top-selling product in the lidocaine segment, announce the Lidocaine Plus product line with the introduction of the Salonpas® Lidocaine Plus Pain Relieving Cream and the Salonpas® Lidocaine Plus Pain Relieving Liquid.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/153e6261-2eae-4aa2-89bd-9556ffbd0806
“The Lidocaine Plus products contain two powerful anesthetics including long-lasting 4% lidocaine which is the maximum strength available without a prescription and fast-acting 10% benzyl alcohol,” said John Incledon, President & CEO, Hisamitsu America. “The Salonpas Lidocaine Plus products desensitize aggravated nerves for temporary relief of back, neck, shoulder, knee and elbow pain.”
“I have been using the new Salonpas® Lidocaine Plus products to address knee and elbow pain after my rigorous work-outs and found that the cream and liquid worked effectively,” said award-winning journalist Dr. Bob Arnot, M.D., internal medicine, author of twelve books on nutrition and health, host of the Dr. Danger reality TV series, and previously Chief Medical Correspondent for NBC and CBS News, and Chief Foreign Correspondent for MSNBC and NBC. Dr. Arnot is also a Paddleboard World Championship award winner.
Salonpas Lidocaine Plus Pain Relieving Cream (MSRP: $12.99) provides non-greasy, fast-absorbing numbing relief. The Salonpas® Lidocaine Plus Pain Relieving Liquid (MSRP: $12.99) features a no-mess, roller ball applicator that keeps hands clean while providing long-lasting pain relief. All of the Salonpas lidocaine products, including the Lidocaine 4% Pain Relieving Patch, are unscented.
The new Salonpas® Lidocaine Plus Pain Relieving Cream and the Salonpas® Lidocaine Plus Pain Relieving Liquid are available at leading retailers nationwide.
Euromonitor International Limited reports that Salonpas® is world’s number one OTC topical analgesic patch brand. In October 2016, Hisamitsu America launched the Salonpas® Lidocaine 4% Pain Relieving Patch which has become the best-selling product in the lidocaine segment*. The company manufactures their own patches ensuring strict adherence to the highest quality standards. Salonpas® sells 13 patches every second with over 1 million sold daily in the United States.
About Hisamitsu America:
Hisamitsu America is the US division of Hisamitsu Pharmaceutical Co., Inc., founded in 1847, which has specialized in patch technology since the introduction of its Salonpas line of patches in 1934. Salonpas®, which gained early acceptance in Japan and now sells in over 50 countries, has pioneered the development of topical patches to relieve everyday aches and pains. Today, the Salonpas® Pain Relief Patch is the first and only FDA-approved OTC pain patch. For more information, visit www.salonpas.us.
*#1 in $ Sales for the Building Calendar Year 2017 ending 9/10/17 among Lidocaine ingredient products (Category: External Analgesics)
Media Contact: Nancy Thompson, Vorticom, Inc. 212.532.2208; [email protected]


Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Instagram Outage Disrupts Thousands of U.S. Users
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 



